Under the influence of Leon Rosenberg, Bristol-Myers Squibb's research department was one of the industry most active early-stage deal makers. Now, Bristol has a new head of research, former Pfizer head of discovery research, Peter Ringrose, who is already talking about reducing the number of early-stage and platform deals to focus instead on deals that will produce INDs within two years of signing the collaboration.
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.